Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$3.25 +0.8%	$2.97	$1.05 ▼ $3.97	$362.25M	1.92	712,621 shs	724,346 shs
AMPH Amphastar Pharmaceuticals	$30.26 -0.8%	$24.48	$20.39 ▼ $53.96	$1.42B	0.76	650,258 shs	316,391 shs
ETNB 89BIO	$9.42 +0.9%	$9.75	$4.16 ▼ $11.84	$1.39B	1.28	1.51 million shs	1.13 million shs
SNDX Syndax Pharmaceuticals	$16.32 +0.4%	$11.35	$8.58 ▼ $22.50	$1.40B	0.74	3.02 million shs	2.24 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	+1.74%	+3.86%	+3.20%	+15.55%	+5.39%
AMPH Amphastar Pharmaceuticals	+0.49%	+2.94%	+37.10%	+18.92%	-37.11%
ETNB 89BIO	-0.21%	+2.64%	-1.99%	-4.79%	+2.19%
SNDX Syndax Pharmaceuticals	+2.59%	+3.30%	+69.91%	+53.11%	-21.86%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADCT ADC Therapeutics	1.3776 of 5 stars	3.5	1.0	0.0	0.6	0.8	0.6
AMPH Amphastar Pharmaceuticals	3.3919 of 5 stars	1.2	1.0	3.7	3.6	4.2	1.3
ETNB 89BIO	2.3286 of 5 stars	3.5	1.0	0.0	4.0	0.8	0.6
SNDX Syndax Pharmaceuticals	3.9211 of 5 stars	4.5	0.0	4.4	2.5	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADCT ADC Therapeutics	3.00	Buy	$7.75	138.83% Upside
AMPH Amphastar Pharmaceuticals	2.40	Hold	$31.60	4.43% Upside
ETNB 89BIO	3.00	Buy	$26.63	182.64% Upside
SNDX Syndax Pharmaceuticals	3.00	Buy	$38.00	132.84% Upside

Current Analyst Ratings Breakdown

Latest ADCT, AMPH, SNDX, and ETNB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/26/2025	AMPH Amphastar Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$28.00 ➝ $32.00
8/25/2025	ETNB 89BIO	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $29.00
8/14/2025	ETNB 89BIO	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
8/13/2025	ADCT ADC Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
8/12/2025	AMPH Amphastar Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$36.00
8/8/2025	AMPH Amphastar Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$30.00 ➝ $25.00
8/8/2025	ETNB 89BIO	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$12.00 ➝ $11.00
8/6/2025	SNDX Syndax Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/5/2025	SNDX Syndax Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$46.00 ➝ $51.00
8/5/2025	SNDX Syndax Pharmaceuticals	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$43.00 ➝ $56.00
7/29/2025	ETNB 89BIO	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADCT ADC Therapeutics	$70.84M	5.15	N/A	N/A	($1.77) per share	-1.83
AMPH Amphastar Pharmaceuticals	$731.97M	1.92	$4.97 per share	6.09	$16.29 per share	1.86
ETNB 89BIO	N/A	N/A	N/A	N/A	$3.52 per share	N/A
SNDX Syndax Pharmaceuticals	$23.68M	59.37	N/A	N/A	$1.83 per share	8.92

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADCT ADC Therapeutics	-$157.85M	-$1.57	N/A	N/A	N/A	-220.00%	N/A	-53.73%	11/6/2025 (Estimated)
AMPH Amphastar Pharmaceuticals	$159.52M	$2.67	11.33	9.20	N/A	18.64%	20.76%	9.68%	11/5/2025 (Estimated)
ETNB 89BIO	-$367.08M	-$3.61	N/A	N/A	N/A	N/A	-94.48%	-80.92%	11/6/2025 (Estimated)
SNDX Syndax Pharmaceuticals	-$318.76M	-$3.89	N/A	N/A	N/A	-428.48%	-130.47%	-56.12%	11/4/2025 (Estimated)

Latest ADCT, AMPH, SNDX, and ETNB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	ADCT ADC Therapeutics	-$0.36	-$0.50	-$0.14	-$0.50	$17.82 million	$18.84 million
8/7/2025	Q2 2025	ETNB 89BIO	-$0.49	-$0.71	-$0.22	-$0.71	N/A	N/A
8/4/2025	Q2 2025	SNDX Syndax Pharmaceuticals	-$1.01	-$0.83	+$0.18	-$0.83	$26.64 million	$37.96 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADCT ADC Therapeutics	N/A	N/A	N/A	N/A	N/A
AMPH Amphastar Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ETNB 89BIO	N/A	N/A	N/A	N/A	N/A
SNDX Syndax Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADCT ADC Therapeutics	N/A	4.93	4.66
AMPH Amphastar Pharmaceuticals	0.80	3.29	2.21
ETNB 89BIO	0.07	15.19	15.19
SNDX Syndax Pharmaceuticals	2.06	4.71	4.55

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADCT ADC Therapeutics	41.10%
AMPH Amphastar Pharmaceuticals	65.09%
ETNB 89BIO	N/A
SNDX Syndax Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ADCT ADC Therapeutics	5.40%
AMPH Amphastar Pharmaceuticals	27.50%
ETNB 89BIO	2.60%
SNDX Syndax Pharmaceuticals	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADCT ADC Therapeutics	310	112.50 million	106.42 million	Optionable
AMPH Amphastar Pharmaceuticals	2,028	46.49 million	33.71 million	Optionable
ETNB 89BIO	40	148.31 million	144.45 million	Optionable
SNDX Syndax Pharmaceuticals	110	86.14 million	82.61 million	Optionable

ADCT, AMPH, SNDX, and ETNB Headlines

Recent News About These Companies

Syndax Announces Participation in September Investor Conferences

August 26 at 7:00 AM | globenewswire.com

Candriam S.C.A. Has $5.53 Million Stock Position in Syndax Pharmaceuticals, Inc. $SNDX

August 24, 2025 | marketbeat.com

Syndax Pharmaceuticals, Inc. $SNDX Shares Bought by Aberdeen Group plc

August 24, 2025 | marketbeat.com

Deutsche Bank AG Has $2.52 Million Position in Syndax Pharmaceuticals, Inc. $SNDX

August 22, 2025 | marketbeat.com

Dennis Podlesak Sells 19,200 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Stock

August 20, 2025 | marketbeat.com

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Director Dennis Podlesak Sells 19,200 Shares

August 20, 2025 | marketbeat.com

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Acquired by Algert Global LLC

August 19, 2025 | marketbeat.com

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Director Sells $298,368.00 in Stock

August 19, 2025 | insidertrades.com

Regulatory Milestone and Analyst Optimism Fuel Momentum for Syndax Pharmaceuticals

August 18, 2025 | insidermonkey.com

BTIG Raises Syndax Pharmaceuticals (SNDX) PT to $56 Following Strong Q2 Revenue from Revuforj, Niktimvo

August 18, 2025 | msn.com

Syndax Pharmaceuticals (NASDAQ:SNDX) Trading Up 4.4% - Time to Buy?

August 16, 2025 | marketbeat.com

Syndax Pharmaceuticals (SNDX) Is Up 15.8% After Revenue Surges in Q2 2025 Results Has Sentiment Shifted?

August 15, 2025 | finance.yahoo.com

Aigen Investment Management LP Buys Shares of 24,158 Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

August 15, 2025 | marketbeat.com

Does Syndax (SNDX) Have the Potential to Rally 158.36% as Wall Street Analysts Expect?

August 14, 2025 | zacks.com

Syndax Pharmaceuticals: A Tale Of Two Drug Launches

August 13, 2025 | seekingalpha.com

Syndax Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:SNDX)

August 13, 2025 | marketbeat.com

FDA Priority Review and Revenue Growth Drive Short-Term Upswing for Syndax Pharmaceuticals

August 13, 2025 | insidermonkey.com

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Average Recommendation of "Buy" by Brokerages

August 11, 2025 | marketbeat.com

Analysts Just Made A Dazzling Upgrade To Their Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Forecasts

August 10, 2025 | finance.yahoo.com

Syndax Pharmaceuticals’ Earnings Call Highlights Robust Growth

August 9, 2025 | theglobeandmail.com

Syndax Pharmaceuticals (SNDX) Gets a Buy from Goldman Sachs

August 9, 2025 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADCT, AMPH, SNDX, and ETNB Company Descriptions

ADC Therapeutics NYSE:ADCT

$3.24 +0.03 (+0.78%)

Closing price 03:59 PM Eastern

Extended Trading

$3.26 +0.02 (+0.62%)

As of 07:59 PM Eastern

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Amphastar Pharmaceuticals NASDAQ:AMPH

$30.26 -0.23 (-0.75%)

Closing price 04:00 PM Eastern

Extended Trading

$30.26 -0.01 (-0.02%)

As of 05:53 PM Eastern

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

89BIO NASDAQ:ETNB

$9.42 +0.08 (+0.86%)

Closing price 04:00 PM Eastern

Extended Trading

$9.42 0.00 (0.00%)

As of 06:35 PM Eastern

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

Syndax Pharmaceuticals NASDAQ:SNDX

$16.32 +0.06 (+0.37%)

Closing price 04:00 PM Eastern

Extended Trading

$16.64 +0.32 (+1.95%)

As of 07:43 PM Eastern

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time